ZYDUSLIFE - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 4.2
| Stock Code | ZYDUSLIFE | Market Cap | 1,08,100 Cr. | Current Price | 1,074 ₹ | High / Low | 1,120 ₹ |
| Stock P/E | 29.3 | Book Value | 235 ₹ | Dividend Yield | 0.09 % | ROCE | 16.6 % |
| ROE | 16.5 % | Face Value | 1.00 ₹ | DMA 50 | 1,016 ₹ | DMA 200 | 960 ₹ |
| Chg in FII Hold | -0.11 % | Chg in DII Hold | 0.12 % | PAT Qtr | 1,806 Cr. | PAT Prev Qtr | 343 Cr. |
| RSI | 57.0 | MACD | 24.8 | Volume | 13,76,593 | Avg Vol 1Wk | 14,18,194 |
| Low price | 836 ₹ | High price | 1,120 ₹ | PEG Ratio | 0.93 | Debt to equity | 0.31 |
| 52w Index | 84.0 % | Qtr Profit Var | -35.8 % | EPS | 35.4 ₹ | Industry PE | 32.1 |
📊 ZYDUSLIFE shows strong fundamentals with bullish technical momentum. The RSI at 57.0 indicates healthy momentum, while the MACD at 24.8 confirms upward bias. Current price (1,074 ₹) is above both the 50DMA (1,016 ₹) and 200DMA (960 ₹), reflecting sustained strength. ROCE (16.6%) and ROE (16.5%) highlight efficiency, while the P/E of 29.3 vs industry average of 32.1 suggests fair valuation. EPS of 35.4 ₹ and PEG ratio of 0.93 indicate balanced growth prospects. However, quarterly PAT declined (1,806 Cr. vs 343 Cr. previous quarter), raising caution.
💡 Optimal Entry Price: Around 1,050–1,065 ₹ (near DMA support zone).
📈 Exit Strategy if Holding: Consider booking profits near 1,110–1,120 ₹ resistance zone, or trail stop-loss below 1,030 ₹.
Positive
- ✅ Strong ROCE (16.6%) and ROE (16.5%) highlight efficiency.
- ✅ EPS of 35.4 ₹ supports valuation strength.
- ✅ PEG ratio of 0.93 indicates balanced growth prospects.
- ✅ Price above both 50DMA and 200DMA confirms bullish trend.
- ✅ DII holdings increased (+0.12%), showing domestic support.
Limitation
- ⚠️ Quarterly PAT declined significantly (-35.8%).
- ⚠️ Dividend yield of 0.09% is negligible.
- ⚠️ Debt-to-equity ratio of 0.31 indicates moderate leverage.
- ⚠️ FII holdings declined (-0.11%), showing reduced foreign confidence.
Company Negative News
- 📉 Decline in quarterly PAT raises caution.
- 📉 Reduced foreign institutional confidence (-0.11%).
Company Positive News
- 📈 EPS strength (35.4 ₹) provides valuation confidence.
- 📈 Domestic institutional investors increased holdings (+0.12%).
Industry
- 🏭 Industry P/E at 32.1 is slightly higher than ZYDUSLIFE’s 29.3, suggesting fair valuation.
- 🏭 Pharma sector outlook remains stable with steady demand drivers.
Conclusion
🔎 ZYDUSLIFE is a fundamentally strong and technically bullish swing trade candidate. Entry near 1,050–1,065 ₹ offers favorable risk-reward, while exits should be targeted around 1,110–1,120 ₹. Traders should remain cautious due to declining quarterly profits and moderate leverage, maintaining strict stop-loss discipline.
Would you like me to extend this into a peer benchmarking overlay with other pharma stocks, or refine it into an intraday momentum setup for sharper entry/exit timing?